Floatz logo

[68ga]vmt02

Melanoma, Mucosal

Perspective TherapeuticsradiopharmaceuticalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Melanoma, Mucosal cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Melanoma Institute Australia
Phase 3BB
Tyrosinase Peptide
University of Southern California
Phase 3BB
INTERFERON ALFA-2B
Shanghai Junshi Bioscience Co., Ltd.
Phase 3B
Ifa
Craig L Slingluff, Jr
Phase 2B
Ipilimumab
Melanoma Institute Australia
Phase 3B

View all 50 →

Same molecule, other indications

[68ga]vmt02 is also rated in:

uveal melanomaDormant
CC
Indicative ·
47 / 100
View asset →
melanomaDormant
CC
Indicative ·
46 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →